Catalog No.
Product Name
Application
Product Information
Citations
-
STING Agonist
MK-2118 is a GMP-synthesized STING agonist that activates the stimulator of interferon genes pathway, enhancing innate immune responses. This compound demonstrates potential in inhibiting advanced or metastatic solid tumors as well as lymphomas. Its ability to modulate immune activity makes MK-2118 a valuable tool for cancer immunotherapy research. -
STING Agonist
STING agonist-15 is a potent stimulator of the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in immune surveillance and response to tumors. This compound enhances the production of type I interferons and other cytokines, promoting anti-tumor immunity and modulating inflammatory responses. It is particularly valuable for cancer research and studying immune-related therapeutic approaches. -
STING Agonist
IACS-8803 is a potent cyclic dinucleotide STING agonist that acts by activating the stimulator of interferon genes (STING) pathway, leading to enhanced immune responses. This compound demonstrates significant systemic antitumor efficacy, making it a valuable tool for cancer immunotherapy research. Its ability to modulate the immune microenvironment positions IACS-8803 as a promising candidate for studies focused on tumor immunogenicity and therapeutic interventions. -
STING Agonist
STING agonist-8 is a highly effective STING agonist, demonstrating an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells. This compound enhances the activity of the STING pathway, making it valuable for research applications focused on cancer immunotherapy and innate immune signaling. STING agonist-8 can facilitate studies exploring the therapeutic potential of STING-mediated immune responses. -
STING Agonist
STING agonist-46 is a potent STING agonist that activates the stimulator of interferon genes (STING) signaling pathway, leading to the phosphorylation of TBK1 and IRF3 as well as the secretion of key cytokines such as IFN-β and IP-10. By directly binding to STING, it enhances thermal stability and elicits significant anti-tumor effects in mouse models, including B16F10, CT26, and 4T1. This compound is suitable for research applications focused on cancer immunotherapy and the elucidation of STING-related immune responses. -
STING Agonist
ZSA-51 is a potent STING agonist that exhibits significant anticancer activity. This compound enhances the immune response by remodeling the immune microenvironment in both tumor tissues and lymph nodes. Its ability to stimulate STING pathways makes it a valuable tool for cancer immunotherapy research. -
STING Inhibitor
STING-IN-5 is a potent inhibitor of the STING pathway, specifically targeting the STING protein to attenuate LPS-induced nitric oxide synthesis in macrophages, with an IC50 value of 1.15 μM. This compound effectively reduces inflammatory responses, making it valuable for research focused on anti-inflammatory diseases and sepsis. Its ability to modulate immune responses highlights its potential in elucidating the role of STING in various pathological contexts. -
STING Agonist
Dazostinag is a potent agonist of the stimulator of interferon genes (STING) protein, demonstrating significant antineoplastic activity. This compound activates the STING pathway, leading to enhanced immune responses against tumors. Additionally, Dazostinag can be utilized as a payload in the synthesis of antibody-drug conjugates (ADCs), providing a valuable tool for targeted cancer therapies. -
STING Agonist
E7766 disodium is a macrocycle-bridged agonist that targets the Stimulator of Interferon Genes (STING) pathway, exhibiting a dissociation constant (Kd) of 40 nM. It demonstrates significant pan-genotypic activity and potent antitumor effects, making it a valuable reagent for cancer immunotherapy research. This compound is ideal for studies focusing on enhancing immune responses through STING activation. -
STING Agonist
IACS-8779 is a potent stimulator of interferon genes (STING) agonist, which activates the STING pathway to enhance immune responses. This compound demonstrates significant systemic antitumor efficacy, making it a valuable tool in cancer research and immunotherapy applications. Its ability to stimulate innate immune responses positions it as a promising candidate for further exploration in oncological studies. -
STING Agonist
BI 7446 is a cyclic dinucleotide (CDN)-based stimulator of interferon genes (STING) agonist that exhibits potent and selective activity. This compound effectively activates all five STING variants within cells, promoting immune-mediated tumor rejection. BI 7446 is suitable for applications in immuno-oncology research, facilitating the exploration of tumor immunity mechanisms. -
STING Agonist
IACS-8779 disodium is a potent stimulator of interferon genes (STING) agonist that elicits a strong activation of the STING signaling pathway. This compound demonstrates significant systemic antitumor efficacy, highlighted by its superior performance in inducing anti-tumor responses in the B16 murine model of melanoma. IACS-8779 disodium is ideal for research applications focused on cancer immunotherapy and the modulation of innate immune responses. -
STING Agonist
STING agonist-51 is a potent bis-benzimidazole compound that targets the STING (Stimulator of Interferon Genes) pathway. It activates STING to enhance the innate immune response, making it a valuable tool for cancer research. This agonist can be used to investigate immune modulation and its therapeutic potential in oncology. -
STING Modulator
STING modulator-4 (compound AIH05) is a competitive modulator of the Stimulator of Interferon Genes (STING), exhibiting a Ki of 0.0933 μM for the R232H variant of STING. This compound demonstrates biological activity with an EC50 value exceeding 10 μM for phosphorylated IRF3 in THP-1 cells. STING modulator-4 is significant for research in immunology and enhances understanding of STING-mediated signaling pathways. -
STING Agonist
STING agonist-28 is a non-nucleotide small-molecule that serves as a potent agonist for the Stimulator of Interferon Genes (STING) pathway. It activates STING, leading to the phosphorylation of key proteins including TBK1 and IRF3. This compound significantly enhances the production of pro-inflammatory cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells, making it valuable for immunotherapy research. Additionally, STING agonist-28 demonstrates antiviral activity against various SARS-CoV strains, highlighting its potential in antiviral research applications. -
STING Ligand
STING ligand-2 is a selective ligand for the stimulator of interferon genes (STING) pathway. This compound is integral in the development of PROTAC degraders, specifically STING-IN-10, enabling targeted protein degradation. Its key biological activity is the enhancement of immune responses, making it valuable for research in immunotherapy and cancer treatment applications. -
STING Agonist
STING Agonist-24 is a small-molecule STING agonist that activates the STING pathway, leading to increased phosphorylation of STING, TBK1, and IRF3. This compound enhances the expression of key pro-inflammatory cytokines and chemokines, including IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5, in tumor cells. Additionally, STING Agonist-24 demonstrates antiviral activity against various strains of SARS-CoV, making it a valuable tool for research in immunotherapy and viral pathogenesis. -
STING Agonist
STING agonist-42 is a potent agonist of the stimulator of interferon genes (STING) pathway. It effectively activates STING in THP-1 and RAW 264.7 cells, demonstrating EC50 values of 0.06 μM and 14.15 μM, respectively. This compound can be utilized in research focused on immune modulation and the exploration of STING-related signaling pathways in various biological contexts. -
STING Agonist
C-di-IMP (Cyclic-di-IMP) is a small molecule that acts as a stimulator of the STING (Stimulator of Interferon Genes) pathway. It promotes immune activation and has significant implications in the study of cancer immunotherapy. This compound is valuable for research aimed at enhancing anti-tumor immunity and understanding the role of STING in modulating immune responses. -
STING Activator
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea that selectively activates the stimulator of interferon genes (STING) pathway. With an EC50 of 18 nM, it enhances the immune response, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity positions it for potential applications in cancer treatment and infectious disease models. -
STING Agonist
STING agonist-31 is a potent stimulator of the STING pathway, exhibiting EC50 values of 0.24 μM for human STING (h-STING) and 39.51 μM for mouse STING (m-STING). This compound demonstrates significant antitumor activity, making it an important tool for cancer research. It is suitable for studying the mechanisms of innate immunity and potential therapeutic applications in oncology. -
STING Agonist
STING Agonist-27 is a non-nucleotide small-molecule compound designed to activate the STING (Stimulator of Interferon Genes) pathway. This agonist showcases significant biological activity against various strains of SARS-CoV, making it valuable for research in antiviral mechanisms and immune modulation. Its application in studies targeting STING activation provides insights into therapeutic strategies for combating viral infections and enhancing innate immunity. -
STING Agonist
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. It effectively activates immune responses, leading to reduced tumor volume in preclinical mouse models of breast cancer. This compound is valuable for research in immunology and cancer therapy, contributing insights into immune modulation and tumor microenvironment interactions. -
PROTAC STING Degrader
PROTAC STING Degrader-2 is a targeted protein degrader that specifically induces the degradation of the Stimulator of Interferon Genes (STING) through a covalent interaction with STING and an E3 ubiquitin ligase. With a DC50 value of 0.53 μM, this compound facilitates the study of STING's biological functions, particularly in the context of autoinflammatory and autoimmune diseases. This reagent is instrumental for researchers exploring the therapeutic potential and role of STING in immune regulation. -
STING Inhibitor
STING-IN-14 is a potent STING inhibitor with an IC50 value of 0.6 nM. This compound effectively suppresses the activation of the IRF pathway in THP1-DualTM cells, making it a valuable tool for studying the role of STING in immune responses. STING-IN-14 is particularly relevant for research focused on autoimmune diseases, contributing to a better understanding of disease mechanisms and potential therapeutic interventions. -
STING Agonist
STING agonist-13 is an agonist of the stimulator of interferon genes (STING), promoting cancer immunity through STING-mediated immune activation. This compound effectively stimulates STING downstream signaling pathways, enhancing type I interferon responses. In preclinical studies, STING agonist-13 has demonstrated a significant reduction in tumor volume and the establishment of immunological memory, suggesting potential applications in cancer immunotherapy. -
STING Antagonist
STING antagonist-3 is a highly effective antagonist of the stimulator of interferon genes (STING) with an IC50 of 2.3 nM against human wild-type STING, as well as against the gain-of-function mutants N154S and V155M. This compound has been shown to inhibit the production of IFN-α2a in stimulated human whole blood and to reduce IP-10 levels in activated human dermal microvascular endothelial cells (HMVEC-d). STING antagonist-3 is valuable for research in autoimmune diseases, autoinflammatory diseases, interferonopathies, and fibrotic disorders. -
STING Agonist
diABZI-a1 is an orthosteric STING agonist that demonstrates an EC50 of 117 nM for the induction of IFNβ in human peripheral blood mononuclear cells (PBMCs). This compound is particularly relevant for research applications focused on monogenic autoinflammatory diseases, such as SAVI syndrome. Its ability to specifically activate the STING pathway makes diABZI-a1 a valuable tool for investigating immune responses and potential therapeutic interventions. -
STING Agonist
STING agonist-44 is a potent and selective agonist targeting the STING pathway. With an EC50 value of 5.68 µM for IRF induction in THP1 cells and 2.212 µM in RAW cells, this compound effectively stimulates the production of type I interferons and pro-inflammatory cytokines, such as CXCL10 and TNFα. STING agonist-44 is a valuable tool for research into cancer immunotherapy and related inflammatory conditions. -
STING Agonist
STING agonist-9 is a potent agonist of the STING (Stimulator of Interferon Genes) pathway, exhibiting an EC50 of 1.2 nM for human STING and 32.82 μM for mouse STING. This compound is known for its significant antitumor activity, making it a valuable tool for investigating immune responses in cancer research. STING agonist-9 is applicable in studies focused on immune activation and tumor microenvironment modulation. -
STING Modulator
STING modulator-5 is an inhibitor of the stimulator of interferon genes (STING) pathway, displaying a pIC50 value of 9.5. This compound effectively antagonizes peripheral blood mononuclear cells (PBMC) with a pIC50 of 8.1 and demonstrates activity against THP-1 cells. STING modulator-5 is a valuable tool for studying immunological diseases and exploring therapeutic avenues targeting STING-related signaling pathways. -
STING Inhibitor
STING modulator-3 is a selective STING inhibitor that targets the R232 variant of STING, exhibiting an inhibition constant (Ki) of 43.1 nM in scintillation proximity assays. This compound does not influence IRF-3 activation or TNF-β induction in THP-1 cells, making it a valuable tool for studying STING-mediated signaling pathways and their implications in immune responses and inflammatory diseases. Its specificity and potency provide researchers with a resource for exploring STING-related mechanisms in various biological contexts. -
STING Agonist
Parent CDN is a cyclic dinucleotide that acts as a Stimulator of Interferon Genes (STING) agonist. It has demonstrated significant anti-tumor activity by enhancing the innate immune response. This compound is utilized in research aimed at understanding immune modulation and cancer immunotherapy. -
STING Agonist
SAP-04 is a potent STING agonist that activates the stimulator of interferon genes pathway, enhancing innate immune responses. This compound demonstrates significant immunomodulatory effects, making it a valuable tool in cancer therapy research. Its oral bioactivity provides convenience for in vivo studies, facilitating the exploration of immune-mediated mechanisms in tumor immunology. -
STING Agonist
(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide is a potent STING (stimulator of interferon genes) agonist. It exhibits a significant inhibitory effect on 3H-cGAMP binding to STING, with an IC50 value of 14 μM. This compound is valuable for research applications in tumor biology and immune response modulation, particularly in the context of cancer immunotherapy. -
hSTING Modulator
Clonixeril (NSC 335504) is a non-nucleotide modulator of human STING (hSTING), exhibiting a unique dual mechanism of action. It acts as a weak agonist at micromolar concentrations while demonstrating antagonistic properties of the hSTINGWT pathway at low femtomolar and attomolar levels. Clonixeril effectively reduces hSTING oligomerization, proving useful in elucidating the complexities of STING signaling and its role in immune responses. This compound serves as a valuable tool for research in immunology and drug discovery targeting STING-related pathways. -
STING Agonist
STING agonist-29 is a small-molecule agonist targeting the stimulator of interferon genes (STING). This compound demonstrates the ability to activate the STING pathway, leading to the induction of type I interferons and pro-inflammatory cytokines. It is particularly notable for its antiviral activity against SARS-CoV strains, making it a valuable tool for research focused on innate immunity and viral infection responses. -
STING Agonist
STING Agonist-43 is a selective STING (Stimulator of Interferon Genes) agonist that activates the cGAMP-dependent STING signaling pathway, with an EC50 of 20.53 μM. This compound enhances STING oligomerization, leading to increased activation and subsequent immune response. In preclinical studies, STING agonist-43 demonstrated antitumor efficacy in a mouse melanoma model, making it a valuable tool for investigating cancer immunity and the potential for immunotherapeutic strategies. -
STING Agonist
STING agonist-34 is a potent stimulator of the STING pathway, exhibiting an IC50 value of 1.15 μM and an EC50 value of 0.38 μM in THP1 cells. This compound activates the cGAS-STING signaling pathway, promoting type I interferon production and enhancing immune responses. STING agonist-34 is applicable in cancer research and immunotherapy studies, offering potential insights into tumor microenvironments and therapeutic strategies against malignancies. -
STING Agonist
STING agonist-25 (CF505) is a non-nucleotide small-molecule activator of the Stimulator of Interferon Genes (STING). This compound enhances the phosphorylation of STING, TBK1, and IRF3, leading to elevated levels of pro-inflammatory cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-25 shows potential in antiviral research, particularly against strains of SARS-CoV. -
STING Activator
STING agonist-10 is a potent small molecule cyclic urea that activates the Stimulator of Interferon Genes (STING) pathway, with an EC50 of 2600 nM. This compound enhances the immune response by stimulating the production of type I interferons, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity holds potential for applications in the treatment of various cancers and infectious diseases. -
STING Agonist
BSP16 is a potent agonist of stimulator of interferon genes (STING), functioning through selective activation of the STING pathway. It exhibits significant biological activity in promoting immune responses, making it a valuable tool for cancer research and immunotherapy studies. BSP16 enables researchers to explore the therapeutic potential of STING activation in various malignancies. -
STING Agonist
STING agonist-48 is a selective agonist that activates the Stimulator of Interferon Genes (STING) pathway, demonstrating an EC50 value of 4.02 μM in vitro. It preferentially binds to the transmembrane domain, influencing downstream immune responses. This compound enhances immunogenicity by promoting IgG and Th1/Th2 cytokine responses in humanized STING mice, making it a valuable tool for investigating inflammation-related diseases and potential adjuvant therapies. -
STING Agonist
STING agonist-21 is a potent STING agonist that demonstrates an EC50 of 592.8 nM. It is designed to activate the stimulator of interferon genes (STING) pathway, which plays a crucial role in immune response modulation. This compound is primarily utilized in cancer research to investigate its effects on tumor immunity and potential therapeutic applications in oncological therapies. -
STING Agonist
Ulevostinag (isomer 2) is a selective STING (Stimulator of Interferon Genes) agonist. It activates the STING pathway, leading to enhanced production of type I interferons and pro-inflammatory cytokines. This compound is primarily utilized in research focused on cancer immunotherapy, infectious diseases, and autoimmune disorders to investigate the therapeutic potential of STING activation in modulating immune responses. -
STING Agonist
STING agonist-38 is a potent agonist of the stimulator of interferon genes (STING), demonstrating an EC50 of 0.05 μM in THP1 cells. This compound exhibits notable oral bioactivity and can effectively activate STING-mediated immune responses. It is valuable for research in immuno-oncology and pathogen response studies. -
STING Modulator
STING modulator-7 is a potent modulator of the stimulator of interferon genes (STING), enhancing the signaling pathway associated with innate immune responses. This compound exhibits significant biological activity in activating STING-dependent pathways, promoting type I interferon production and immune cell activation. It is primarily utilized in research applications focused on cancer immunotherapy, infectious disease models, and studies of immune system regulation. -
STING Agonist
Ulevostinag (isomer 3) is a potent STING (Stimulator of Interferon Genes) agonist that functions through the activation of the STING pathway, leading to the induction of type I interferons and other cytokines. This compound has demonstrated significant biological activity in promoting anti-tumor immune responses, making it an essential tool for cancer immunotherapy research. Its ability to modulate immune signaling pathways positions Ulevostinag (isomer 3) as a valuable reagent in the study of immune activation and anti-cancer strategies. -
STING Agonist
Ulevostinag (isomer 4) is a potent STING (Stimulator of Interferon Genes) agonist that activates the STING signaling pathway, leading to the production of type I interferons and other pro-inflammatory cytokines. This compound enhances the immune response, making it valuable for research in cancer immunotherapy and infectious disease. Ulevostinag (isomer 4) serves as an important tool for studying STING-mediated pathways and their role in immune modulation. -
TpoR Agonist
Totrombopag is an orally active thrombopoietin receptor (TpoR) agonist. It activates TpoR, triggering an intracellular signaling cascade involving JAK2 kinase and the transcription factor Stat5, which is crucial for the regulation of megakaryocyte growth and differentiation into platelets. This compound is valuable for research into platelet production and the biology of megakaryocytes.
